Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of elinzanetant for endocrine therapy-induced vasomotor symptoms in women with or at high risk for hormone receptor-positive breast cancer
MOH_2022-11-03_012155Phase 3Active, not recruiting
- Sponsor
- Bayer Consumer Health
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in vasomotor symptoms comparing Elinzanetant 120 mg for 52 weeks with Placebo for 12 weeks then elinzanetant 120 mg for 40 weeks (2 arms). Started Nov 2022; status: active, not recruiting.
02
Drugs
elinzanetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on MOH_2022-11-03_012155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-11-03_012155.